Investigate the Dosimetric and Potential Clinical Benefits Utilizing Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost Technique for Locally Advanced Pancreatic Cancer: A Comparison Between Photon and Proton Beam Therapy

Peilin Liu, Xianshu Gao, Zishen Wang, Xiaomei Li, Xi Cao, Chenghao Jia, Mu Xie, Feng Lyu, Shiyu Shang, Xuanfeng DingFrontiers in Oncology 2021 · DOI

Abstract

The results indicated that the tumor locations could play a critical role in determining clinical benefits among different treatment modalities. Two-field IMPT could be a better option for LAPC patients whose tumors are located in the head of the pancreas. It provides lower severe toxicity for the stomach and duodenum. Nevertheless, VMAT is preferred for the body with better protection for the possibility of gastric bleed.

Introduction

Pancreatic cancer remains one of the most challenging malignancies to treat due to the pancreas's proximity to highly sensitive organs at risk (OARs), such as the stomach, duodenum, and small intestine. Standard radiation therapy often reaches a "dose ceiling," where increasing the dose to effectively kill the tumor risks life-threatening gastrointestinal (GI) complications. To overcome this, researchers have explored Stereotactic Body Radiation Therapy (SBRT) with a Simultaneous Integrated Boost (SIB), which delivers a high dose to the tumor core while maintaining a standard dose to the periphery. This study compares the efficacy and safety of photon-based Volumetric Modulated Arc Therapy (VMAT) against Intensity Modulated Proton Therapy (IMPT) for this aggressive approach.

Methods and Materials

This retrospective dosimetric study analyzed 19 patients with locally advanced pancreatic cancer (LAPC) treated at Peking University First Hospital. The cohort included 13 cases with tumors in the pancreatic head and 6 in the pancreatic body. The prescribed dose was 30 GyE to the target volume and 45 GyE to the boost area over five fractions.

Three treatment plans were generated and compared for each patient:

  1. VMAT: The current clinical standard using photons.
  2. Two-field IMPT: Utilizing two proton beam angles.
  3. Three-field IMPT: Utilizing three proton beam angles to enhance coverage.

Beyond physical dose measurements, the study employed Normal Tissue Complication Probability (NTCP) models to predict clinical risks, such as gastric bleeds and severe GI toxicity. Robustness testing was also conducted to evaluate how setup errors and proton range uncertainties affected plan quality.

Key Results

Geography as a Determinant of Modality

The study's primary finding is that the superiority of proton therapy is highly dependent on tumor location. For tumors located in the pancreatic head, 2-field IMPT was significantly more effective at sparing the stomach and duodenum. The median maximum dose to the stomach was reduced to 18.6 GyE with protons compared to 21.82 GyE with VMAT. This translated to a predicted gastric bleed risk of 3.42% for protons versus 6.73% for photons.

Dose distribution comparison for pancreatic head (A) and body (B) tumors across VMAT and IMPT techniques.

Conversely, for tumors in the pancreatic body, VMAT proved safer. The maximum dose to the stomach was lower with photons (30.93 GyE) than with 2-field IMPT (33.08 GyE), resulting in a lower predicted risk of gastric bleed (8.67% vs. 12.83%). This is largely attributed to the "overshoot" problem; while protons stop at a specific depth (the Bragg Peak), range uncertainties in the pancreatic body can cause the beam to deposit energy directly into the stomach.

Dose-Volume Histograms (DVH) for target volumes and organs-at-risk in pancreatic head (A) and body (B) cases.

Beam Configuration and Robustness

While 3-field IMPT provided the most stable target coverage against uncertainties, it increased the "entrance dose"—the total radiation absorbed by healthy tissue before reaching the tumor. This resulted in higher mean doses to the stomach, duodenum, and intestine compared to the 2-field approach.

Discussion and Limitations

The use of NTCP models highlights that even small differences in physical dose can lead to significant variations in predicted patient outcomes. However, several limitations must be considered. This was a small-scale "in silico" study with 19 patients; larger clinical trials are necessary to validate these predicted risks. Additionally, the study assumed a fixed Relative Biological Effectiveness (RBE) of 1.1 for protons, which may underestimate toxicity at the distal edge of the beam.

Future advancements, such as online adaptive radiotherapy to account for internal organ motion and the use of injectable hydrogel spacers to physically separate the stomach from the pancreas, may further refine the clinical application of these technologies.

Conclusion

For LAPC patients undergoing SIB-SBRT, the choice between photon and proton therapy should be individualized based on tumor anatomy. Protons offer a clear advantage for pancreatic head tumors, while photons remain the preferred modality for tumors in the pancreatic body to minimize the risk of gastric complications.

Summary updated

Abstract

The results indicated that the tumor locations could play a critical role in determining clinical benefits among different treatment modalities. Two-field IMPT could be a better option for LAPC patients whose tumors are located in the head of the pancreas. It provides lower severe toxicity for the stomach and duodenum. Nevertheless, VMAT is preferred for the body with better protection for the possibility of gastric bleed.
BibTeX
@inproceedings{liu2021investigate,
  author = {Peilin Liu and Xianshu Gao and Zishen Wang and Xiaomei Li and Xi Cao and Chenghao Jia and Mu Xie and Feng Lyu and Shiyu Shang and Xuanfeng Ding},
  title = {{Investigate the Dosimetric and Potential Clinical Benefits Utilizing Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost Technique for Locally Advanced Pancreatic Cancer: A Comparison Between Photon and Proton Beam Therapy}},
  booktitle = {Frontiers in Oncology},
  year = {2021},
  doi = {10.3389/fonc.2021.747532},
}
Figure